NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Bausch + Lomb and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Bausch + Lomb and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On March ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other jur ...

For the quarter ended March 2025, Bausch + Lomb (BLCO) reported revenue of $1.14 billion, up 3.5% over the same period last year. EPS came in at -$0.07, compared to $0.07 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.15 billion, representing a surprise of -0.86%. The company delivered an EPS surprise of -333.33%, with the consensus EPS estimate being $0.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Bausch + Lomb (BLCO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -333.33%. A quarter ago, it was expected that this company would post earnings of $0.24 per share when it actually produced earnings of $0.25, delivering a surprise of 4.17%.Over the last four quarters, the company has surpassed c ...

Financial Performance - Total reported revenue for Q1 2025 was $1.137 billion, a 3% increase from $1.099 billion in Q1 2024, with a 5% increase on a constant currency basis[4] - GAAP net loss attributable to Bausch + Lomb for Q1 2025 was $212 million, compared to a net loss of $167 million in Q1 2024[13] - Adjusted EBITDA excluding Acquired IPR&D for Q1 2025 was $126 million, down from $180 million in Q1 2024, a decrease of $54 million[16] - Adjusted net income (non-GAAP) for Q1 2025 was $24 million, compared to a loss of $54 million in Q1 2024, resulting in an adjusted EPS of $0.07 versus a loss of $0.15[46] - Total revenues for Q1 2025 were $1,137 million, a 3.5% increase from $1,099 million in Q1 2024, driven by product sales of $1,133 million[45] - The net loss attributable to Bausch + Lomb Corporation for Q1 2025 was $212 million, compared to a net loss of $167 million in Q1 2024, with a diluted loss per share of $0.60 versus $0.48[45] - Adjusted EBITDA (non-GAAP) for Q1 2025 was $98 million, down from $180 million in Q1 2024, reflecting a decrease of 45.6%[50] Segment Performance - Vision Care segment revenue was $656 million, a 3% increase from $635 million in Q1 2024, with a 5% increase on a constant currency basis[9] - Surgical segment revenue was $214 million, a 9% increase from $197 million in Q1 2024, with an 11% increase on a constant currency basis[10] - Pharmaceuticals segment revenue remained flat at $267 million, with a 1% increase on a constant currency basis[11] - Vision Care segment revenue increased to $669 million in Q1 2025, up 5% from $635 million in Q1 2024[51] - Surgical segment revenue grew by 11% to $218 million in Q1 2025, compared to $197 million in Q1 2024[51] - Pharmaceuticals segment revenue remained stable at $269 million in Q1 2025, with a slight increase of 1% from $267 million in Q1 2024[51] Operational Costs - Operating loss for Q1 2025 was $83 million, compared to an operating income of $6 million in Q1 2024, a change of $89 million[12] - Cash flow used in operations for Q1 2025 was $25 million, down from $41 million in Q1 2024[14] - Cost of goods sold (excluding amortization and impairments) increased to $481 million in Q1 2025 from $423 million in Q1 2024, reflecting a 13.7% rise[45] - Selling, general and administrative expenses rose to $563 million in Q1 2025, up from $504 million in Q1 2024, marking an increase of 11.7%[45] - Research and development expenses were $86 million in Q1 2025, slightly up from $82 million in Q1 2024, indicating a 4.9% increase[45] - The company incurred $38 million in restructuring, integration, and transformation costs in Q1 2025, compared to $28 million in Q1 2024[50] Guidance and Future Outlook - Full-year 2025 revenue guidance updated to $5.000 billion - $5.100 billion, reflecting a constant currency growth of approximately 4.5% - 6.5%[18] - Bausch + Lomb's 2025 full-year guidance is based on current management expectations and includes anticipated growth in key products like XIIDRA® and MIEBO®[25] - The company is undergoing a separation from Bausch Health Companies Inc., which may involve transferring equity interests to shareholders, contingent on achieving targeted debt leverage ratios[25] - Future business development transactions may lead to recurring costs related to Acquired In-Process Research and Development (IPR&D) as the company continues to pursue growth opportunities[36] Risks and Challenges - Risks associated with the separation include potential business disruptions, regulatory approvals, and market conditions that may affect the transaction's completion[26] - The anticipated impact of tariffs and global supply chain disruptions is a concern for the company's revenue and expenses moving forward[26] - The company is actively managing the expected impact of inflation and interest rate fluctuations on its financial performance[26] - The voluntary recall of certain enVista® IOL products is expected to affect market supply, with enhanced inspection protocols in place to address quality concerns[26] Financial Metrics and Adjustments - The company reported a total of $191 million in non-GAAP adjustments for Q1 2025, compared to $158 million in Q1 2024[46] - Amortization of intangible assets decreased to $67 million in Q1 2025 from $74 million in Q1 2024[47] - The company utilized constant currency revenue growth metrics to assess performance, indicating that foreign exchange fluctuations can obscure underlying business trends[39] - Management emphasized the importance of adjusted financial metrics for evaluating operational performance and making strategic decisions[38] - The company has excluded costs related to share-based compensation and separation activities from its financial measures to provide clearer insights into operational performance[34]

Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight comp ...

Patent and Regulatory Environment - As of February 12, 2025, the company owns or exclusively licenses approximately 2,584 granted patents worldwide, with about 465 being U.S. patents[52] - Approximately 78% of the company's issued patents will expire within the next 10 years, with 23 patents set to expire in both 2025 and 2026, and 36 patents in 2027[52] - The company relies on a combination of regulatory and patent rights to protect the value of its investment in product development[51] - The U.S. Hatch-Waxman Act provides non-patent regulatory exclusivity for five years from the first FDA approval of a new drug compound[54] - The company has approximately 127 pending U.S. patent applications, indicating ongoing innovation efforts[52] - The FDA may designate a product as an orphan drug if it treats a disease affecting fewer than 200,000 individuals in the U.S., granting seven years of marketing exclusivity[58] - The company is subject to extensive government regulations regarding the research, development, testing, and marketing of pharmaceutical products and medical devices[63] - Compliance with manufacturing regulations, including good manufacturing practices, is enforced by the FDA and Health Canada[67] - The company faces periodic audits of its facilities by regulatory agencies, ensuring adherence to compliance standards[68] - Price control restrictions on pharmaceutical products are present in many countries where the company operates[69] Workforce and Operations - The company operates in approximately 100 countries with a global commercial team of about 4,300 employees[89] - In the United States, the company has around 1,150 employees dedicated to selling and marketing contact lenses, lens care, consumer eye health, surgical, and prescription pharmaceutical products[90] - The international commercial footprint includes approximately 3,150 employees and a network of distribution partners[90] - As of December 31, 2024, the company had approximately 13,500 employees, with 7,200 in production and 4,300 in sales and marketing[104] - The company launched a new global performance management program in 2024 to enhance employee performance monitoring and alignment[113] Financial Performance and Risks - In 2024, customers accounting for 10% or more of total revenues were McKesson Corporation and Cardinal Health, Inc., each contributing 10%[93] - Approximately 37% of product sales for 2024 are produced in total or in part by third-party manufacturers under manufacturing arrangements[102] - The company’s revenues tend to be weighted toward the second half of the year, with first-quarter sales typically lower due to patient co-pays and deductibles resetting[118] - As of December 31, 2024, the company had $3,441 million in variable rate debt and $1,400 million in fixed rate debt[578] - A 100 basis-points increase or decrease in interest rates would have an annualized pre-tax effect of approximately $34 million on earnings and cash flows[578] - The estimated fair value of the company's fixed rate debt as of December 31, 2024, was $1,449 million[578] - A 1% change in foreign currency exchange rates would impact shareholders' equity by approximately $27 million[577] - The company is exposed to multiple foreign currencies, including the Euro, Chinese yuan, Russian ruble, and Japanese yen[577] - Further strengthening of the U.S. dollar or devaluation of foreign currencies will negatively impact reported revenue and results[577] - If interest rates increase by 100 basis-points, the fair value of fixed rate debt would decrease by approximately $35 million[578] - If interest rates decrease by 100 basis-points, the fair value of fixed rate debt would increase by approximately $31 million[578] - Changes in interest rates could adversely affect the company's earnings and cash flows due to its variable rate debt[578] Compliance and Governance - The company is subject to extensive U.S. federal and state health care marketing and fraud regulations, including the federal False Claims Act and Anti-Kickback Statute, which impose significant compliance obligations[70] - The company must comply with the Health Insurance Portability and Accountability Act (HIPAA) and various state laws regarding the privacy and security of health-related information, which may require substantial costs for compliance[73] - The General Data Protection Regulation (GDPR) imposes strict obligations on the processing of personal data, with potential fines of up to 4% of global annual revenue or €20 million for violations[76] - The company is subject to the Personal Information Protection Law (PIPL) in China, which regulates the transfer of personal data outside of China, effective from March 1, 2023[79] - The regulatory framework for data privacy and security is rapidly evolving, which may lead to increased compliance costs and risks for the company[82] - The company is developing an integrated ESG program to comply with evolving regulations related to environmental, social, and governance matters[86] Corporate Social Responsibility - The ONE by ONE Recycling program has collected over 94 million used contact lenses and related items since its launch in November 2016[117] - The company’s commitment to corporate social responsibility includes initiatives aimed at disease prevention and improving patient outcomes globally[116] Supply Chain and Manufacturing - The company operates 23 manufacturing facilities across 10 countries, including the U.S., Ireland, and China, focusing on specific product categories[98] - The company’s global supply team is actively managing inflationary and supply-chain challenges due to ongoing macroeconomic conditions[103] - The company faces pressures from government authorities and third-party payors to limit or regulate the price of medical products, which can result in lower average realized prices[83]

Financial Data and Key Metrics Changes - The company reported total revenue of $1.28 billion for Q4 2024, reflecting an 11% increase and 10% organic growth. For the full year, total revenue was $4.791 billion, representing a 17% increase and 10% organic growth [24][25]. - Adjusted gross margin for Q4 was 62.5%, and for the full year, it was 62.6%, up 160 basis points compared to the previous year [39]. - Adjusted EBITDA for Q4 was $259 million, representing a 14% growth year-over-year, while for the full year, it was $878 million, up 20% compared to 2023 [40]. Business Line Data and Key Metrics Changes - Vision Care revenue for Q4 was $723 million, an 11% increase, with full-year revenue of $2.739 billion, up 10% [26]. - The Surgical segment reported Q4 revenue of $231 million, a 15% increase, with full-year revenue of $843 million, representing 11% growth [32]. - The Pharma segment generated $326 million in revenue for Q4, a 7% increase, and $1.209 billion for the full year, reflecting a 45% growth [34]. Market Data and Key Metrics Changes - The U.S. contact lens revenue grew by 17% in Q4, while international revenue increased by 11%. For the full year, U.S. revenue was up 12% and international revenue was up 11% [30]. - The company saw a 75% growth in Daily SiHy lenses in Q4, contributing to the overall contact lens revenue growth of 13% for the quarter [29]. Company Strategy and Development Direction - The company is focused on innovation and execution, with a commitment to long-term growth and a robust pipeline of new products [10][11]. - The strategy includes optimizing manufacturing processes and leveraging AI to enhance sales force effectiveness [9]. - The company aims to maintain its leadership position in the eye care market by addressing unmet needs and expanding its product offerings [8][12]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the fundamentals of the eye care market, expecting each segment to deliver growth in 2025 [42]. - The company anticipates currency headwinds of approximately $100 million to revenue and $20 million to adjusted EBITDA in 2025 due to the strengthening U.S. dollar [44]. - Management highlighted the importance of continued investment in R&D and direct-to-consumer campaigns to drive future growth [45][48]. Other Important Information - The company expects full-year revenue for 2025 to be in the range of $4.95 billion to $5.05 billion, reflecting constant currency growth of approximately 5.5% to 7.5% [42]. - Adjusted EBITDA guidance for 2025 is set between $900 million to $950 million, excluding potential one-time IPR&D charges [43]. Q&A Session Summary Question: Insights on customer growth and execution - Management noted significant improvements in operational excellence and customer service, leading to a 10% organic revenue growth CAGR over the past two years [75][76]. Question: Contact lens growth sustainability - Management expressed optimism about the contact lens market, highlighting strong growth driven by new products and direct-to-consumer capabilities [87][88]. Question: Expectations for Miebo and Xiidra - Management indicated high expectations for Miebo's continued growth and noted that Xiidra is expected to see TRx growth momentum in 2025 [100][102]. Question: Market share and transitioning customers - Management confirmed a balanced approach between transitioning existing customers and acquiring new fits, contributing to overall growth [111]. Question: Guidance for 2025 revenue growth - Management explained that the guidance reflects a reasonable starting point, factoring in market dynamics and the impact of the Inflation Reduction Act [116][117].

Core Insights - Bausch + Lomb reported $1.28 billion in revenue for Q4 2024, a year-over-year increase of 9.1% and a surprise of +1.17% over the Zacks Consensus Estimate of $1.27 billion [1] - The company's EPS for the same period was $0.25, compared to $0.24 a year ago, resulting in an EPS surprise of +4.17% [1] Revenue Breakdown - Vision Care revenues reached $723 million, exceeding the estimated $708.34 million, reflecting a +9.2% change year-over-year [4] - Pharmaceuticals revenues were reported at $326 million, slightly below the estimated $335.50 million, with a year-over-year increase of +6.2% [4] - Product sales totaled $1.28 billion, surpassing the average estimate of $1.26 billion, marking a +9.2% year-over-year change [4] - Surgical revenues amounted to $231 million, exceeding the average estimate of $215.26 million, representing a +13.2% year-over-year increase [4] - Other revenues were reported at $5 million, matching the two-analyst average estimate, with no year-over-year change [4] Stock Performance - Bausch + Lomb shares have returned -4.8% over the past month, contrasting with the Zacks S&P 500 composite's +4.7% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]